David C. Remy
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David C. Remy.
Annual Reports in Medicinal Chemistry | 1980
David C. Remy; Gregory E. Martin
Publisher Summary With respect to the DA theory of schizophrenia, arguments have recently been presented that increased dopaminergic transmission produces positive symptomatology of schizophrenia (Type I syndrome, equivalent to an acute state of the disease), while other factors, such as structural changes in the brain, produce the negative symptomatology of schizophrenia (Type II syndrome, equivalent to the defect state of chronic sd1izophrenia). Research in Parkinsons disease, wherein the degeneration of DA neurons in the nigrostriatal pathway results in a pathological DA deficiency, continues to center on the therapeutic use of directly acting DA agonists. Such agonists are also being studied in schizophtenic patients as alternatives to conventional neuroleptic drugs. Moreover, a selective presynaptic DA receptor agonist may have the beneficial effect of a reduced potential for extrapyramidal side effects and tardive dyskinesia. The D-1 (linked to adenylate cyclase) and D-2 (not linked to adenylate cyclase) DA receptor classification of Kebabian and Calne remains the most widely accepted of the DA receptor concepts, and the nature of these receptors has been further characterized. Attention has continued to focus on the dopaminergic attributes of 2-aminotetralin derivatives. The nature and number of nuclear substituent, as well as their substitution pattern and the nature of substituent on the nitrogen atom, greatly influence the pharmacological profiles of such compounds by affecting their regional distribution and locus of action.
Journal of Medicinal Chemistry | 1964
Charles Heidelberger; David G. Parsons; David C. Remy
Biochemistry | 1994
Kurt Freund; Kundan P. Doshi; Stanley L. Gaul; David A. Claremon; David C. Remy; John J. Baldwin; Steven M. Pitzenberger; Andrew M. Stern
Archive | 1991
John J. Baldwin; David A. Claremon; Jason Matthew Elliott; Gerald S. Ponticello; David C. Remy; Harold G. Selnick
Journal of Medicinal Chemistry | 1997
Harold G. Selnick; Nigel Liverton; John J. Baldwin; John W. Butcher; David A. Claremon; Jason Matthew Elliott; Roger M. Freidinger; Stella A. King; Brian Libby; Charles J. Mcintyre; David A. Pribush; David C. Remy; Garry R. Smith; Andrew Tebben; Nancy K. Jurkiewicz; Joseph J. Lynch; Joseph J. Salata; Michael C. Sanguinetti; Peter K. S. Siegl; Donald E. Slaughter; Kamlesh P. Vyas
Journal of Pharmacology and Experimental Therapeutics | 1994
Joseph J. Lynch; Audrey A. Wallace; R. F. Stupienski; E. P. Baskin; C. M. Beare; S. D. Appleby; Joseph J. Salata; Nancy K. Jurkiewicz; Michael C. Sanguinetti; R. B. Stein; J. R. Gehret; T. Kothstein; David A. Claremon; Jason Matthew Elliott; John W. Butcher; David C. Remy; John J. Baldwin
Journal of Organic Chemistry | 1976
David C. Remy; Kenneth E. Rittle; Cecilia A. Hunt; Mark B. Freedman
Journal of Organic Chemistry | 1983
Yves Girard; Joseph G. Atkinson; Patrice C. Belanger; José J. Fuentes; Joshua Rokach; C. Stanley Rooney; David C. Remy; Cecilia A. Hunt
Archive | 1991
John J. Baldwin; David C. Remy; David A. Claremon
Archive | 1991
John J. Baldwin; David A. Claremon; Jason Matthew Elliott; Gerald S. Ponticello; David C. Remy; Harold G. Selnick